{"id":"https://openalex.org/W2902234722","doi":"https://doi.org/10.1007/s12325-018-0840-8","title":"Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States","display_name":"Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States","publication_year":2018,"publication_date":"2018-11-29","ids":{"openalex":"https://openalex.org/W2902234722","doi":"https://doi.org/10.1007/s12325-018-0840-8","mag":"2902234722","pmid":"https://pubmed.ncbi.nlm.nih.gov/30499067","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6318235"},"language":"en","primary_location":{"id":"doi:10.1007/s12325-018-0840-8","doi":"https://doi.org/10.1007/s12325-018-0840-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s12325-018-0840-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s12325-018-0840-8.pdf","source":{"id":"https://openalex.org/S27230875","display_name":"Advances in Therapy","issn_l":"0741-238X","issn":["0741-238X","1865-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in Therapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s12325-018-0840-8.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040177032","display_name":"Christine L. Baker","orcid":"https://orcid.org/0000-0001-7532-7399","observed_orcids":["https://orcid.org/0000-0001-7532-7399"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Christine L. Baker","raw_affiliation_strings":["Pfizer, Inc., New York, NY, USA. christine.l.baker@pfizer.com","Pfizer, Inc., New York, NY, USA"],"raw_orcid":"https://orcid.org/0000-0001-7532-7399","affiliations":[{"raw_affiliation_string":"Pfizer, Inc., New York, NY, USA. christine.l.baker@pfizer.com","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer, Inc., New York, NY, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013717649","display_name":"Amol D. Dhamane","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amol D. Dhamane","raw_affiliation_strings":["Bristol-Myers Squibb, Lawrenceville, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Lawrenceville, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054571533","display_name":"Jack Mardekian","orcid":"https://orcid.org/0000-0003-4851-5161","observed_orcids":["https://orcid.org/0000-0003-4851-5161"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jack Mardekian","raw_affiliation_strings":["Pfizer, Inc., New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Inc., New York, NY, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057689988","display_name":"Oluwaseyi Dina","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Oluwaseyi Dina","raw_affiliation_strings":["Pfizer, Inc., New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Inc., New York, NY, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087610563","display_name":"Cristina Russ","orcid":"https://orcid.org/0000-0001-7248-9712","observed_orcids":["https://orcid.org/0000-0001-7248-9712"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cristina Russ","raw_affiliation_strings":["Pfizer, Inc., New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Inc., New York, NY, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054707936","display_name":"Lisa C. Rosenblatt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa Rosenblatt","raw_affiliation_strings":["Bristol-Myers Squibb, Lawrenceville, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Lawrenceville, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026378192","display_name":"Melissa Lingohr-Smith","orcid":"https://orcid.org/0000-0002-3046-9278","observed_orcids":["https://orcid.org/0000-0002-3046-9278"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Melissa Lingohr-Smith","raw_affiliation_strings":["Novosys Health, Green Brook, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novosys Health, Green Brook, NJ, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064854156","display_name":"Brandy Menges","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brandy Menges","raw_affiliation_strings":["Novosys Health, Green Brook, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novosys Health, Green Brook, NJ, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080303082","display_name":"Jay Lin","orcid":"https://orcid.org/0000-0002-6376-8469","observed_orcids":["https://orcid.org/0000-0002-6376-8469"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jay Lin","raw_affiliation_strings":["Novosys Health, Green Brook, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novosys Health, Green Brook, NJ, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031195290","display_name":"Anagha Nadkarni","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anagha Nadkarni","raw_affiliation_strings":["Bristol-Myers Squibb, Lawrenceville, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Lawrenceville, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5040177032"],"corresponding_institution_ids":["https://openalex.org/I180857899"],"apc_list":{"value":4790,"currency":"USD","value_usd":4790},"apc_paid":{"value":4790,"currency":"USD","value_usd":4790},"fwci":2.6422,"has_fulltext":true,"cited_by_count":24,"citation_normalized_percentile":{"value":0.9123141,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":90,"max":98},"biblio":{"volume":"36","issue":"1","first_page":"162","last_page":"174"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10285","display_name":"Venous Thromboembolism Diagnosis and Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2724","display_name":"Internal Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/direct-oral-anticoagulants","display_name":"direct oral anticoagulants","score":0.9169999957084656},{"id":"https://openalex.org/keywords/non-valvular-atrial-fibrillation","display_name":"non-valvular atrial fibrillation","score":0.9980000257492065},{"id":"https://openalex.org/keywords/drug-switching","display_name":"drug switching","score":0.8790000081062317},{"id":"https://openalex.org/keywords/anticoagulation-discontinuation","display_name":"anticoagulation discontinuation","score":0.9240000247955322},{"id":"https://openalex.org/keywords/apixaban","display_name":"apixaban","score":0.9850000143051147},{"id":"https://openalex.org/keywords/rivaroxaban","display_name":"rivaroxaban","score":1.0},{"id":"https://openalex.org/keywords/dabigatran","display_name":"dabigatran","score":1.0},{"id":"https://openalex.org/keywords/warfarin","display_name":"warfarin","score":0.9319999814033508},{"id":"https://openalex.org/keywords/stroke-prevention","display_name":"stroke prevention","score":0.8090000152587891},{"id":"https://openalex.org/keywords/real-world-claims-data","display_name":"real-world claims data","score":0.453000009059906},{"id":"https://openalex.org/keywords/united-states","display_name":"United States","score":0.3319999873638153},{"id":"https://openalex.org/keywords/pharmacoepidemiology","display_name":"pharmacoepidemiology","score":0.7149999737739563},{"id":"https://openalex.org/keywords/anticoagulation-safety","display_name":"anticoagulant safety","score":0.38199999928474426}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9445645809173584},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.8769171237945557},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.8726623058319092},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6238102316856384},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5609989762306213},{"id":"https://openalex.org/C2778661090","wikidata":"https://www.wikidata.org/wiki/Q420262","display_name":"Rivaroxaban","level":4,"score":0.46920767426490784},{"id":"https://openalex.org/C198451711","wikidata":"https://www.wikidata.org/wiki/Q327657","display_name":"Rheumatology","level":2,"score":0.44998690485954285},{"id":"https://openalex.org/C23276603","wikidata":"https://www.wikidata.org/wiki/Q158230","display_name":"Pharmacoepidemiology","level":3,"score":0.42261937260627747},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.3960193395614624},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.3139330744743347},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.25982823967933655},{"id":"https://openalex.org/C2426938","wikidata":"https://www.wikidata.org/wiki/Q3355478","display_name":"Medical prescription","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069552","descriptor_name":"Rivaroxaban","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000069604","descriptor_name":"Dabigatran","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000074822","descriptor_name":"Treatment Adherence and Compliance","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001281","descriptor_name":"Atrial Fibrillation","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014859","descriptor_name":"Warfarin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D020521","descriptor_name":"Stroke","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1007/s12325-018-0840-8","doi":"https://doi.org/10.1007/s12325-018-0840-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s12325-018-0840-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s12325-018-0840-8.pdf","source":{"id":"https://openalex.org/S27230875","display_name":"Advances in Therapy","issn_l":"0741-238X","issn":["0741-238X","1865-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in Therapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5305234","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6318235","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6318235","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6318235","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Adv Ther","raw_type":"Text"},{"id":"pmid:30499067","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30499067","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in therapy","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1007/s12325-018-0840-8","doi":"https://doi.org/10.1007/s12325-018-0840-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s12325-018-0840-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s12325-018-0840-8.pdf","source":{"id":"https://openalex.org/S27230875","display_name":"Advances in Therapy","issn_l":"0741-238X","issn":["0741-238X","1865-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2902234722.pdf","grobid_xml":"https://content.openalex.org/works/W2902234722.grobid-xml"},"referenced_works_count":28,"referenced_works":["https://openalex.org/W1660970868","https://openalex.org/W1913182214","https://openalex.org/W2038329412","https://openalex.org/W2066380890","https://openalex.org/W2096246254","https://openalex.org/W2097854437","https://openalex.org/W2135241452","https://openalex.org/W2136489990","https://openalex.org/W2155779925","https://openalex.org/W2162508946","https://openalex.org/W2170350621","https://openalex.org/W2218242202","https://openalex.org/W2281540926","https://openalex.org/W2343949636","https://openalex.org/W2433454023","https://openalex.org/W2511163880","https://openalex.org/W2513537003","https://openalex.org/W2520573665","https://openalex.org/W2620376388","https://openalex.org/W2623715034","https://openalex.org/W2735068920","https://openalex.org/W2738405916","https://openalex.org/W2750836949","https://openalex.org/W2751640892","https://openalex.org/W2753731981","https://openalex.org/W2763895023","https://openalex.org/W2785683904","https://openalex.org/W2800941304"],"related_works":["https://openalex.org/W2933129157","https://openalex.org/W4366977771","https://openalex.org/W2967596543","https://openalex.org/W3194115802","https://openalex.org/W4402185636","https://openalex.org/W4388595895","https://openalex.org/W2763895023","https://openalex.org/W2980772371","https://openalex.org/W3106348194","https://openalex.org/W3208942900"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Continuous":[1],"usage":[2],"of":[3,83,185],"direct":[4],"oral":[5],"anticoagulants":[6],"(DOACs)":[7],"among":[8],"nonvalvular":[9],"atrial":[10],"fibrillation":[11],"(NVAF)":[12],"patients":[13,35,63,186,229,260,286,298,315],"is":[14],"essential":[15],"to":[16,79,94,112,290,308,314],"maintain":[17],"stroke":[18],"prevention.":[19],"We":[20],"examined":[21],"switching":[22,110,183,258],"and":[23,66,69,85,100,118,131,165,191,196,215,241,275,323],"discontinuation":[24,121,210],"rates":[25,111,184,211],"for":[26,90,224,256],"the":[27,37,52,95,106,138,177,180,203,207,295],"three":[28,204],"most":[29],"frequently":[30],"initiated":[31,42,146,156,167],"DOACs":[32],"in":[33,36,226],"NVAF":[34,84,139,300],"USA.":[38],"METHODS:":[39],"Patients":[40,76],"who":[41],"apixaban,":[43,189],"rivaroxaban,":[44,190],"or":[45,116,310,319],"dabigatran":[46,168,192,242,276],"(index":[47],"event/date)":[48],"were":[49,77,123,193,212,287,305],"identified":[50],"from":[51],"Pharmetrics":[53],"Plus":[54],"claims":[55],"database":[56],"(Jan":[57],"1,":[58],"2013-Sep":[59],"30,":[60],"2016,":[61],"includes":[62],"with":[64,126,188,231,262,299,303,317],"commercial":[65],"Medicare":[67],"coverage)":[68],"grouped":[70],"into":[71],"cohorts":[72],"by":[73],"index":[74,96,119,208],"DOAC.":[75],"required":[78],"have":[80],"a":[81,252],"diagnosis":[82],"continuous":[86],"health":[87],"plan":[88],"enrollment":[89],"12":[91],"months":[92,104],"prior":[93],"date":[97],"(baseline":[98],"period)":[99],"at":[101],"least":[102],"3":[103],"during":[105],"follow-up":[107,178],"period.":[108],"Drug":[109],"any":[113],"other":[114],"DOAC":[115,120,209],"warfarin":[117],"rate":[122],"evaluated":[124],"separately":[125],"descriptive":[127],"statistics,":[128],"Kaplan-Meier":[129],"analysis,":[130],"multivariable":[132],"Cox":[133],"regression":[134],"analysis.":[135],"RESULTS:":[136],"Of":[137],"study":[140],"population":[141],"(n":[142,148,158,169],"=":[143,149,159,170],"41,864),":[144],"37%":[145],"apixaban":[147,304],"15,352;":[150],"mean":[151,161,172],"age":[152,162,173],"62":[153],"years),":[154,164],"51%":[155],"rivaroxaban":[157,232,266,318],"21,250;":[160],"61":[163,174],"13%":[166],"5262;":[171],"years).":[175],"During":[176],"period,":[179],"unadjusted":[181],"drug":[182,257],"treated":[187,230,261,285,302,316],"3.6%,":[194],"6.3%,":[195],"11.1%,":[197],"respectively":[198,217],"(p":[199,218],"<":[200,219,239,249,273,283],"0.001":[201],"across":[202],"cohorts);":[205],"while":[206],"52.8%,":[213],"60.3%,":[214],"62.9%,":[216],"0.001).":[220],"After":[221],"we":[222],"controlled":[223],"differences":[225],"patient":[227],"characteristics,":[228],"(HR":[233,243,267,277],"1.8;":[234],"95%":[235,245,269,279],"CI":[236,246,270,280],"1.6-2.0;":[237],"p":[238,248,272,282],"0.001)":[240,250,274,284],"3.4;":[244],"3.0-3.8,":[247],"had":[251],"significantly":[253],"greater":[254],"likelihood":[255],"than":[259],"apixaban.":[263],"Also,":[264],"both":[265],"1.1;":[268],"1.1-1.2,":[271],"1.3;":[278],"1.2-1.3,":[281],"more":[288],"likely":[289,307],"discontinue":[291,311],"treatment.":[292],"CONCLUSION:":[293],"In":[294],"real-world":[296],"setting,":[297],"newly":[301],"less":[306],"switch":[309],"treatment":[312],"compared":[313],"dabigatran.":[320],"FUNDING:":[321],"Pfizer":[322],"Bristol-Myers":[324],"Squibb.":[325]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-12-11T00:00:00"}